** Shares of Neuren Pharmaceuticals NEU.AX rise as much as 8.1% to A$14.350, their highest since Oct. 7
** Biopharmaceutical reports Rett syndrome drug Daybue's 9 months net sales exceeded full-year threshold of $250 mln
** Co sees full-year income to be in the range of A$216 mln to A$218 mln ($141.83 mln to $143.14 mln)
** Stock down 43.1% YTD as of 0046 GMT
($1 = 1.5230 Australian dollars)
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。